• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Chest. Antibiotic Dosing in Multiple Organ Dysfunction Syndrome

Giuseppe

Emeritus
[Source: Chest, full text: (LINK). Abstract, edited.]

Antibiotic Dosing in Multiple Organ Dysfunction Syndrome

  1. Marta Ulldemolins, PharmD, 2 Jason A. Roberts, PhD, BPharm(Hons), 3 Jeffrey Lipman, MD and 4 Jordi Rello, MD, PhD
Author Affiliations
  1. From the Burns, Trauma and Critical Care Research Centre (Drs Ulldemolins, Roberts, and Lipman), The University of Queensland, Brisbane, QLD, Australia; Critical Care Department (Drs Ulldemolins and Rello), Vall d?Hebron University Hospital, Vall d?Hebron Institut de Recerca (VHIR), Universitat Aut?noma de Barcelona, Barcelona, Spain; Centro de Investigaci?n Biom?dica En Red de Enfermedades Respiratorias (CIBERES) (Drs Ulldemolins and Rello), Barcelona, Spain; and Department of Intensive Care Medicine (Drs Roberts and Lipman) and Pharmacy Department (Dr Roberts), Royal Brisbane and Women?s Hospital, Herston, Brisbane, QLD, Australia.
  1. Correspondence to:
    Jordi Rello, MD, PhD, Critical Care Department, Vall d?Hebron University Hospital, Institut de Recerca Vall d?Hebron-UAB, Passeig de la Vall d?Hebron 119-129, 08035 Barcelona, Spain; e-mail: jrello.hj23.ics@gencat.cat
Abstract


Although early and appropriate antibiotic therapy remains the cornerstone of success for the treatment of septic shock, few data exist to guide antibiotic dose optimization in critically ill patients, particularly those with multiple organ dysfunction syndrome (MODS). It is well known that MODS significantly alters the patient?s physiology, but the effects of these variations on pharmacokinetics have not been reviewed concisely. Therefore, the aims of this article are to summarize the disease-driven variations in pharmacokinetics and pharmacodynamics and to provide antibiotic dosing recommendations for critically ill patients with MODS. The main findings of this review are that the two parameters that vary with greatest significance in critically ill patients with MODS are drug volume of distribution and clearance. Disease- and clinician-driven changes lead to an increased volume of distribution and lower-than-expected plasma drug concentrations during the first day of therapy at least. Decreased antibiotic clearance is common and can lead to drug toxicity. In summary, ?front-loaded? doses of antibiotic during the first 24 h of therapy should account for the likely increases in the antibiotic volume of distribution. Thereafter, maintenance dosing must be guided by drug clearance and adjusted to the degree of organ dysfunction.
Footnotes
  • Funding/Support: Funded by the National Health and Medical Research Council of Australia [Project Grant 519702; Australian Based Health Professional Research Fellowship 569917 (to Dr Roberts)]; Australia and New Zealand College of Anaesthetists [ANZCA 06/037 and 09/032]; Queensland Health-Health Practitioner Research Scheme; Royal Brisbane and Women?s Hospital Research Foundation (to Drs Roberts and Lipman); and CIBERES [0606036], Ag?ncia de Gesti? d?Ajuts Universitaris i de Recerca [09/SGR/1226], and Fondo de Investigaci?n Sanitaria [07/90960] (to Drs Ulldemolins and Rello).
  • Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
Abbreviations

<DL><DT>AKI <DD>acute kidney injury <DT>AUC<SUB>0-24</SUB> <DD>area under the concentration curve over 0 to 24 h <DT>CL <DD>clearance <DT>Cmax <DD>peak concentration <DT>CrCL <DD>creatinine clearance <DT>? T > MIC <DD>time over minimum inhibitory concentration <DT>GFR <DD>glomerular filtration rate <DT>MDRD <DD>modified diet in renal disease <DT>MIC <DD>minimum inhibitory concentration <DT>MODS <DD>multiple organ dysfunction syndrome <DT>PK/PD <DD>pharmacokinetic/pharmacodynamic <DT>RRT <DD>renal replacement therapy <DT>TDM <DD>therapeutic drug monitoring <DT>Vd <DD>volume of distribution</DD></DL>
  • Received September 13, 2010.
  • Accepted January 3, 2011.
  • ? 2011 American College of Chest Physicians
-
-------
 
Back
Top Bottom